

(19) World Intellectual Property
Organization
International Bureau




(43) International Publication Date
27 October 2005 (27.10.2005)

PCT

(10) International Publication Number
WO 2005/100544 A2

- (51) International Patent Classification⁷: C12N 1/21, (74) Agents: WILSON, M., Lisa et al.; Duane Morris LLP, 380 C07H 21/02 Lexington Avenue, New York, NY 10168 (US).
- (21) International Application Number: PCT/US2005/012462
- (22) International Filing Date: 12 April 2005 (12.04.2005)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/561,660 12 April 2004 (12.04.2004) US
- (71) Applicant (for all designated States except US): THE TRUSTEES OF PRINCETON UNIVERSITY [US/US]; Princeton University, 4 New South Building, Princeton, NJ 08544-0336 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): LENZ, Derrick, H. [US/US]; 201 Spruce Mill Lane, Scotch Plains, NJ 07076 (US). MOK, Kenny, C. [US/US]; 3465 Lebon Drive #1727, San Diego, CA 92122 (US). WINGREEN, Ned, S. [US/US]; 150 Patton Avenue, Princeton, NJ 08540 (US). BASSLER, Bonnie, L. [US/US]; 39 Pine Street, Princeton, NJ 08542 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SMALL RNAs AND BACTERIAL STRAINS INVOLVED IN QUORUM SENSING



(57) Abstract: Quorum-sensing bacteria communicate with extracellular signal molecules called autoinducers to allow community-wide synchronization of gene expression. The present invention relates to the identification of *Vibrio harveyi* and *Vibrio Cholerae* protein Hfq as mediating interactions between small, regulatory RNAs (sRNAs) and specific messenger RNA (mRNA) targets. Accordingly, the present invention provides nucleic acids encoding the *Vibrio* sRNAs, strains having various deletions and mutations of one or more *qrr* genes encoding these sRNA as well as methods of identifying quorum-sensing regulators. Additionally, the invention relates to an isolated *V. harveyi* Hfq protein and conservative amino acid substitutions thereof as well as nucleic acids encoding those proteins, recombinant methods of producing those proteins and antibodies against those proteins.

Small RNAs and Bacterial Strains Involved in Quorum Sensing

FIELD OF THE INVENTION

[0001] Quorum-sensing bacteria communicate with extracellular signal molecules called autoinducers to allow community-wide synchronization of gene expression. The present invention relates to the identification the *Vibrio harveyi* and *Vibrio cholerae* protein Hfq as mediating interactions between small, regulatory RNAs (sRNAs) and specific messenger RNA (mRNA) targets. Accordingly, the present invention provides nucleic acids encoding the *Vibrio* sRNAs, strains having various deletions and mutations of one or more *qrr* genes encoding these sRNA as well as methods of identifying quorum-sensing regulators. Additionally, the invention relates to an isolated *V. harveyi* Hfq protein and conservative amino acid substitutions thereof as well as nucleic acids encoding those proteins, recombinant methods of producing those proteins and antibodies against those proteins.

BACKGROUND OF THE INVENTION

[0002] Quorum sensing is a process of cell-to-cell communication that bacteria use to assess their population density in order to coordinate the gene expression of the community (Miller *et al.*, 2001). Quorum sensing requires the production, secretion, and detection of extra-cellular signal molecules termed autoinducers. Diverse behaviors are controlled by quorum sensing, but, typically, these behaviors are ones that would be ineffective if only a small group of cells carried them out. Often, bacteria produce and detect multiple autoinducers, some of which are used for intraspecies communication, while others promote interspecies communication (Federle *et al.*, 2003; Fuqua *et al.*, 2001; Xavier *et al.*, 2003).

[0003] The marine bacterium *Vibrio harveyi* produces and detects two autoinducers, AI-1 and AI-2, and these signals control the expression of multiple genes, including those for bioluminescence (luciferase) (Bassler *et al.*, 1993, 1994a; Cao *et al.*, 1989; Chen *et al.*, 2002b), siderophore production (Lilley *et al.*, 2000), colony morphology, metalloprotease production (Mok *et al.*, 2003), and type III secretion (Henke *et al.*, 2004).

[0004] In *V. harveyi*, AI-1 and AI-2 are produced by the synthases LuxM and LuxS, respectively (Bassler *et al.*, 1993; Surette *et al.*, 1999). LuxN detects AI-1, and

LuxPQ detects AI-2 (Fig. 1A) (Bassler *et al.*, 1993, 1994a; Chen *et al.*, 2002b; Freeman *et al.*, 2000b). LuxN and LuxQ are membrane bound, two-component hybrid sensor-kinase proteins. LuxP, which binds AI-2 in the periplasm, is required with LuxQ for the response to AI-2 (Bassler *et al.*, 1994a; Chen *et al.*, 2002b). Sensory information from both systems converges at the phosphorelay protein LuxU, and LuxU transmits the signal to the response regulator LuxO (Bassler *et al.*, 1994b; Freeman *et al.*, 1999, 2000a). A transcriptional activator called LuxR is also required for expression of *lux* (the operon encoding the bioluminescence genes in *V. harveyi*) and other quorum sensing-controlled genes (Henke *et al.*, 2004; Martin *et al.*, 1989; Miyamoto *et al.*, 1994; Showalter *et al.*, 1990).

[0005] The human pathogen *Vibrio cholerae* possesses quorum-sensing systems analogous to the two described above for *V. harveyi* (Miller *et al.*, 2002). The *V. cholerae* autoinducers CAI-1 and AI-2 are synthesized by CqsA and LuxS and detected by CqsS and LuxPQ, respectively (Fig. 1B). *V. cholerae* has an additional system (System 3; Miller *et al.*, 2002). Sensory information from all three systems converges at LuxO. The *V. cholerae* LuxR homolog is called HapR (Jobling *et al.*, 1997). Quorum sensing controls virulence and biofilm formation in *V. cholerae* (Hammer *et al.*, 2003; Kovacikova *et al.*, 2002; Miller *et al.*, 2002; Vance *et al.*, 2003; Zhu *et al.*, 2003; Zhu *et al.*, 2002).

[0006] The *V. harveyi* and *V. cholerae* quorum-sensing circuits operate similarly (Miller *et al.*, 2002). At low cell density, *i.e.*, in the absence of autoinducers, the sensors act as kinases and transfer phosphate via LuxU to LuxO. LuxO-phosphate (LuxO-P) is active and negatively regulates *lux*. At high cell density, *i.e.*, when the autoinducers are present, the sensors act as phosphatases. Phosphate flow through the circuit is reversed, resulting in dephosphorylation and inactivation of LuxO (Freeman *et al.*, 1999, 2000a; Freeman *et al.*, 2000b). Under this condition, the transcriptional regulators LuxR in *V. harveyi* and HapR in *V. cholerae* bind the *lux* promoter and activate transcription (Fig. 1).

[0007] LuxO-P-mediated repression of *lux* is indirect (Lilley *et al.*, 2000). LuxO is homologous to members of the NtrC family of response regulators, which can act either as transcriptional activators or repressors. Those that are activators require the alternative sigma factor σ_{54} for function, while those that are repressors do not (Benson *et al.*, 1994; North *et al.*, 1996; Reitzer *et al.*, 1985; Wingrove *et al.*, 1994; Wu *et al.*, 1997). LuxO is a member of the activator class of NtrC homologs. It has been hypothesized that, at low

cell density, LuxO-P activates the expression of a repressor that controls the downstream target genes.

[0008] The present invention relates to the discovery that multiple, redundant small regulatory RNAs (sRNAs), together with the sRNA binding protein Hfq, fulfill this repressor role. Specifically, at low cell density, the Hfq-sRNA repressor complexes destabilize the *V. harveyi luxR* and *V. cholerae hapR* mRNAs (Fig. 1).

SUMMARY OF THE INVENTION

[0009] One aspect of the present invention relates to sRNAs encoded by the *qrr* genes of *Vibrio* species, *Vibrio* strains containing various deletions of those genes and method to use those strains to identify regulators of quorum sensing.

[0010] In particular, one embodiment provides an isolated nucleic acid encoding an sRNA from a *Vibrio* species. Such sRNAs interact with the Hfq protein from *V. cholerae* (or its equivalent in that species) and are sufficiently complementary to stably bind to a *hapR* mRNA (e.g., in *V. cholerae* or its equivalent in the species such as *luxR* mRNA in *V. harveyi*) and to thereby regulate quorum sensing. Each *qrr* gene is under control of the transcription factor sigma 54 (σ^{54}) and LuxO (or the relevant equivalent) and has a Rho-independent terminator. In *V. cholerae*, the *qrr* genes are located in the intergenic regions between annotated genes. The same is true for the *qrr* genes from *V. parahaemolyticus* and *V. vulnificus* and appears to be the case for *V. harveyi*. The sRNA is from any *Vibrio* species containing *qrr* genes, and is preferably from *V. cholerae*, *V. parahaemolyticus*, *V. vulnificus* or *V. harveyi*. *V. cholerae* has 4 *qrr* genes (*qrr1-qrr4*) whereas *V. parahaemolyticus*, *V. vulnificus* and *V. harveyi* each have five *qrr* genes (*qrr1-qrr5*).

[0011] The nucleotide sequences for the *qrr* genes of the above *Vibrios* is provided, in the case of the DNA, in SEQ ID NOS. 1-19 and in the case of the RNA, in SEQ ID NOS. 20-38. Additionally, the invention provides nucleic acids that encode the sRNAs of the invention and that hybridizes to these sequences under stringent conditions.

[0012] Another aspect of the invention relates to expression vectors that express one or more sRNAs of Claim 1 as well as cells that comprise those vectors and that can be used to produce the one or more sRNAs. For example, sRNA can be produced by culturing cells of the invention for a time and under conditions sufficient to express an sRNA and the sRNA can be recovered by conventional means.

[0013] Yet another aspect of the invention provides isolated *Vibrio* strains that have a deletion or mutation of one or more *qrr* genes. Such strains are useful, among other things, to analyze regulation of quorum sensing and to identify regulators of quorum sensing. These strains are from any *Vibrio* species and, preferably are from *V. cholerae*, *V. parahaemolyticus*, *V. vulnificus* or *V. harveyi*. Any of these strains can have one or more deletions or mutations of any other gene involved in any of the quorum sensing pathways, see, e.g., Fig. 1. Examples of *V. cholerae* strains having deletions of three of the four *qrr* genes include, but are not limited to, DL2998, DL2996, DL2955 or DL2997. Examples of *V. cholerae* strains having deletions of all four *qrr* genes, include, but are not limited to, DL2956, DL3024, DL2953 or DL3020.

[0014] Still another aspect of the invention relates to an isolated *V. harveyi* Hfq protein and conservative amino acid substitutions thereof as well as nucleic acids encoding those proteins, recombinant methods of producing those proteins and antibodies against those proteins.

[0015] A further aspect of the invention provides a method of identifying a quorum-sensing regulator by contacting *Vibrio* cells that have at least one inactivated *qrr* gene with a test compound and assaying a quorum-sensing response to the compound, and with appropriate controls, thereby identify or determine that the compound regulates quorum sensing. This method can readily be adapted for high throughput screening of test compounds. In a preferred embodiment the *Vibrio* cells have no more than one active *qrr* gene. Quorum-sensing responses can be measured by many different techniques, including cell density-dependent changes in light production or in a reporter system. Reporter systems are well known in the art and can be used in conjunction with the lux promoter or other quorum-sensing promoter.

[0016] When measuring light production in cells that have a single active *qrr* gene, the method identifies activators of quorum sensing. When measuring light production in cells with no active *qrr* genes, the method identifies inactivators of quorum sensing. While measurement of light production is preferred, this method can be adapted to use any other measurable parameters indicative of quorum sensing to identify the desired regulators. For measuring light production, the compounds can be tested on *V. harveyi* strains, which are naturally bioluminescent or on any *Vibrio* strain that has been engineered to carry a *lux* operon, usually the *V. harveyi* lux operon. Such strains include,

for example, *V. cholerae*, *V. parahaemolyticus*, *V. vulnificus*, *V. fisherii* and *V. anguillarum*.

BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Fig. 1 graphically illustrates models of the *V. harveyi* and *V. cholerae* quorum-sensing circuits. Fig. 1A shows that two quorum-sensing systems function in parallel to regulate gene expression in *V. harveyi*. Pentagons and triangles represent AI-1 and AI-2, respectively. Fig. 1B shows that three quorum-sensing systems function in parallel to regulate gene expression in *V. cholerae*. The functions making up the third circuit (denoted System 3) remain to be identified. Diamonds and triangles represent CAI-1 and AI-2, respectively. In both circuits, phosphate flows in the direction indicated by the arrows at low cell density and in the opposite direction at high cell density.

[0018] Fig. 2A graphically illustrates the *hfq* locus in *V. harveyi*. *miaA* and *hflC* were not fully sequenced (unsequenced regions are denoted by light-colored shading).

[0019] Fig. 2B shows a plot of bioluminescence versus cell density for *V. harveyi* strains BB120 (WT, squares), JAF78 ($\Delta luxO::cm^+$, diamonds), JAF548 (*luxO* D47E, open triangles), BNL258 (*hfq::Tn5lacZ*, circles), and BNL211 (*luxO* D47E, *hfq::Mini-MulacZ*, closed triangles). Relative light units for *V. harveyi* are defined as counts min⁻¹ ml⁻¹ x 10³/cfu ml⁻¹. Fig. 2C shows bioluminescence versus cell density for *V. cholerae* strains MM227 (WT, squares), MM349 ($\Delta luxO$, diamonds), BH48 (*luxO* D47E, open triangles), DL2078 (Δhfq , circles), and DL2378 (*luxO* D47E, Δhfq , closed triangles). Relative light units for *V. cholerae* are defined as counts min⁻¹ ml⁻¹/OD_{600nm}. In Fig. 2B and 2C, the dotted lines represent the limit of detection for light.

[0020] Fig. 2D is a Western blot showing the following *V. cholerae* strains analyzed for TcpA production: C6706str2 (WT), MM307 ($\Delta luxO$), BH38 (*luxO* D47E), MM194 ($\Delta hapR$), DL2066 (Δhfq), DL2146 (*luxO* D47E, Δhfq), and DL2607 ($\Delta hapR$, Δhfq).

[0021] Fig. 3A presents non-steady state Northern blots which show Hfq regulates the expression of *luxR* and *hapR* posttranscriptionally. *luxR/hapR* transcript stability was analyzed in the following strains: *V. harveyi* JAF548 (*luxO* D47E) and BNL211 (*luxO* D47E, *hfq::Mini-MulacZ*) (left four panels); and *V. cholerae* BH38 (*luxO* D47E) and DL2146 (*luxO* D47E, Δhfq) (right four panels).

[0022] Fig. 3B shows Western blots on lysates for the left panel of *V. harveyi* BB120 (WT), JAF548 (*luxO* D47E), BNL258 (*hfq::Tn5lacZ*), BNL211 (*luxO* D47E, *hfq::Mini-MulacZ*), and for the right panel of *V. cholerae* C6706str2 (WT), BH38 (*luxO* D47E), DL2066 (Δhfq), DL2146 (*luxO* D47E, Δhfq) to measure LuxR and HapR protein, respectively.

[0023] Fig. 4 presents bar graphs demonstrating that LuxO-P and Hfq regulate *hapR* posttranscriptionally. Fig. 4A shows β -galactosidase activity of *hapR-lacZ* transcription in *V. cholerae* DL2106 (WT, $\Delta lacZ$), DL2099 (*luxO* D47E, $\Delta lacZ$), DL2523 (Δhfq , $\Delta lacZ$), and DL2441 (*luxO* D47E, Δhfq , $\Delta lacZ$). Fig. 4B shows β -galactosidase activity of *hapR-lacZ* translation in *V. cholerae* DL2543 (WT, $\Delta lacZ$), DL2542 (*luxO* D47E, $\Delta lacZ$), DL2531 (Δhfq , $\Delta lacZ$), and DL2533 (*luxO* D47E, Δhfq , $\Delta lacZ$). Fig. 4C shows β -galactosidase activity of *hapR-lacZ* promoter activity in *V. cholerae* DL2748 (WT, $\Delta lacZ$), DL2771 (*luxO* D47E, $\Delta lacZ$), DL2703 (Δhfq , $\Delta lacZ$), and DL2698 (*luxO* D47E, Δhfq , $\Delta lacZ$).

[0024] Fig. 5A shows a multiple sequence alignment of the *qrr* genes encoding the sRNAs identified in *V. cholerae*, *V. parahaemolyticus*, *V. vulnificus*, and *V. harveyi*. Annotations for the genes flanking each sRNA are given in the brackets. Numbering of sRNAs is based on orthology of flanking genes. Nucleotides in black indicate perfect alignment. The putative σ^{54} binding site is marked as -12 and -24, the predicted start of transcription is labeled as +1, and the terminator is noted by the line over the sequence.

[0025] Fig. 5B illustrates the lowest-energy secondary-structural predictions for the Qrr sRNAs identified in *V. cholerae*. Bold typeface indicates the regions conserved across all sRNAs in *V. cholerae*, *V. parahaemolyticus*, and *V. vulnificus*.

[0026] Fig. 5C presents an alignment of the complement of the *hapR* UTR (shown in the 3' to 5' direction; SEQ ID NO. 44) with a portion of the Qrr sRNAs identified in *V. cholerae* (shown in the 5' to 3' direction). Fig. 5D presents a similar alignment of the complement of the *luxR* UTR (SEQ ID NO. 45) with a portion of sRNA Qrr1 identified in *V. harveyi*. In Figs. 5C and 5D, the translational start site (Start), the ribosome binding site (RBS), and the transcriptional start site (+1) are indicated. Figs. 5A, 5C and 5D were produced using CLUSTALW (Thompson *et al.*, 1994) and ESPript (Gouet *et al.*, 1999).

[0027] Fig 6 illustrates the regulation of expression of the sRNAs by quorum sensing. For Fig. 6A, RNA isolated from *V. cholerae* C6706str2 (WT), MM307 ($\Delta luxO$), BH38 (*luxO* D47E), BH76 ($\Delta rpoN$) was probed for sRNAs Qrr1, Qrr2, Qrr3, and Qrr4,

and *V. cholerae rpsL* (as a loading control). In the right panel of Fig. 6A, the *hapR* gene was deleted from the same set of strains and probed as described. For Fig. 6B, RNA isolated from *V. harveyi* BB120 (WT), BB721 (*luxO::Tn5lacZ*), JAF548 (*luxO* D47E), and BNL240 (*rpoN::cm^r*) was probed for sRNA Qrr1 with a probe made against *V. harveyi qrr1* and for sRNA Qrr4 with a probe made against *V. cholerae qrr4*. *V. harveyi rpsL* is shown as the loading control.

[0028] Fig. 6C is a bar graph illustrating bioluminescence (RLU) at single time point for *V. cholerae* strains DL3212 (*luxO*) and DL3213 (*luxO* D47E) containing the *qrr1-lux* transcriptional fusion in trans.

[0029] Fig. 7A graphically illustrates that simultaneous deletion of the four sRNAs is required to affect quorum sensing in *V. cholerae*. Fig. 7A shows a plot of bioluminescence versus cell density for *V. cholerae* MM227 (WT, open squares), MM349 ($\Delta luxO$, open diamonds), DL2998 ($\Delta qrr2$, $\Delta qrr3$, $\Delta qrr4$, closed squares), DL2996 ($\Delta qrr1$, $\Delta qrr3$, $\Delta qrr4$, closed diamonds), DL2955 ($\Delta qrr1$, $\Delta qrr2$, $\Delta qrr4$, closed triangles), DL2997 ($\Delta qrr1$, $\Delta qrr2$, $\Delta qrr3$, closed circles), DL2956 ($\Delta qrr1$, $\Delta qrr2$, $\Delta qrr3$, $\Delta qrr4$, open circles).

[0030] Fig. 7B is a bar graph (top panel) illustrating bioluminescence (RLU) at a single time point for *V. cholerae* strains MM227 (WT), MM349 ($\Delta luxO$), BH48 (*luxO* D47E), DL2956 ($\Delta qrr1$, $\Delta qrr2$, $\Delta qrr3$, $\Delta qrr4$), and DL3024 (*luxO* D47E, $\Delta qrr1$, $\Delta qrr2$, $\Delta qrr3$, $\Delta qrr4$). The bottom two panels are Western blots probed for HapR and TcpA production from *V. cholerae* strains C6706str2 (WT), MM307 ($\Delta luxO$), BH38 (*luxO* D47E), DL2953 ($\Delta qrr1$, $\Delta qrr2$, $\Delta qrr3$, $\Delta qrr4$), and DL3020 (*luxO* D47E, $\Delta qrr1$, $\Delta qrr2$, $\Delta qrr3$, $\Delta qrr4$).

[0031] Fig. 8 graphically depicts a rate model showing that mutual destruction of sRNA and its target mRNA produces an ultrasensitive response to the rate of sRNA synthesis. If the rate of sRNA synthesis, k_x , drops below the rate of target mRNA synthesis, k_y , the steady-state pool of target message rises abruptly. In the quorum-sensing circuit, this implies that an ultrasensitive increase in *hapR/luxR* mRNA levels occurs with decreasing levels of LuxO-P as cell density increases. The curves are generated from Equation 7 of Elf *et al.* (2003), which describes the production of two chemical species (the sRNA and the mRNA) that undergo mutual destruction with a second-order rate constant

k_{md} ($= v_{max}/K_x K_y$) and also undergo intrinsic, first-order degradation at a rate μ . In the

curves shown, the one adjustable parameter $k_{md} k_y/\mu^2$ equals 5×10^7 , which is in the regime where degradation of the minority species is primarily due to mutual-destruction processes. Concentrations are given in units of k_y/μ .

DETAILED DESCRIPTION OF THE INVENTION

sRNA Nucleic Acids, *qrr* Genes and Uses

[0032] The decision to transition from acting alone to participating in a group activity is a significant one for bacteria. In vibrios, sophisticated regulatory devices are located at different positions in the quorum-sensing signal-transduction relay to ensure that this decision occurs under the appropriate set of circumstances and with high fidelity. Previously, it was shown that a coincidence detector regulates entry into high cell density mode: the simultaneous presence of multiple autoinducers is required to reverse the direction of phosphoflow through the system and thus to initiate the transition from the individualistic to the group lifestyle (Mok *et al.*, 2003). The coincidence-detection scheme likely protects the quorum-sensing circuit from molecules in the environment that resemble the bona fide autoinducers. This invention relates to the discovery that an ultrasensitive switch involving multiple sRNAs exists to make the commitment step into quorum-sensing mode definitive. This transition is not graded but rather acts as an on/off switch, which turns off behaviors that are useful when carried out alone and turns on behaviors that are productive when carried out as a community.

[0033] Accordingly, one aspect of the invention relates to isolated nucleic acids which encode one or more sRNAs involved in quorum sensing regulation in a *Vibrio* species, wherein the sRNA interacts with a *Vibrio cholerae* Hfq protein or with the corresponding protein from the particular *Vibrio* species; the sRNA has a sequence sufficiently complementary to stably bind to a *V. cholerae* *hapR* mRNA or to the corresponding mRNA from the particular *Vibrio* species. The sRNA as encoded in the *Vibrio* genome is found in an intergenic region and is under transcriptional control of a *V. cholerae* transcription factor sigma 54 (σ^{54}) or the corresponding transcription factor from the particular *Vibrio* species as well as under transcriptional control of a *V. cholerae* LuxO protein or the corresponding protein from the particular *Vibrio* species. The sRNA gene is followed by a Rho-independent terminator.

[0034] Preferred *Vibrio* species include but are not limited to, *V. cholerae*, *V. parahaemolyticus*, *V. vulnificus* or *V. harveyi*. Other *Vibrio* species include *V. fluvialis*,

V. fischerii, *V. hollisae*, *V. alginolyticus*, *V. furnissii*, *V. metschnikovii*, *V. cincinnatiensis*, *V. damsela*, *V. carchariae*, *V. anguillarum*, *V. damsela*, and *V. carchariae*.

[0035] The nucleic acids of the invention are composed of RNA, DNA, stabilized RNA, stabilized DNA or RNA or DNA having unusual or bases or sugars, provided that such molecules function as sRNAs in quorum sensing in accordance with the instant invention. Any of these molecules can be made either recombinantly or synthetically by techniques known to those of ordinary skill in the art. Stabilized RNA and DNA include molecules that have substituted phosphate backbones, such as phosphorothioate groups, or other linkages or moieties known to stabilize RNA and DNA and prevent its degradation.

[0036] *V. parahaemolyticus*, *V. vulnificus* and *V. harveyi* each have five sRNAs. These sRNAs are encoded by the *qrr1-qrr5* genes. *V. cholerae* has four *qrr* genes, namely *qrr1-qrr4*. In one embodiment of the invention, the nucleic acids of the invention comprise any one of the sequences provided in SEQ ID NOS. 1-19 (in the case of DNA) or 20-38 (in the case of RNA) or the complement of any of these sequences. Each of these sequences represent the sRNA encoded by a *qrr* from one of the foregoing *Vibrio* species.

[0037] In another embodiment of the invention, the nucleic acid of the invention consists essentially of an sRNA sequence. In addition, the nucleic acids of the invention, include isolated nucleic acids which hybridize to those encoded in SEQ ID NOS. 1-38 under stringent conditions, and preferably under highly stringent conditions. For example, such nucleic acids are identified by using hybridization and washing conditions of the desired high stringency, e.g., as described in Sambrook et al. (1989) Such nucleic acids can be isolated, cloned and/or sequenced if desired. In a preferred embodiment, the stringent hybridization conditions include a step of hybridizing in 6xSSC at about 45°C followed by one or more washes in 0.1xSSC/0.2% SDS at about 68°C, or equivalently stringent hybridization conditions.

[0038] As used herein, "isolated nucleic acid" means (1) a DNA molecule that is separated from sequences with which it is immediately contiguous (in the 5' and 3' directions) in the naturally occurring genome of the organism from which it was derived or (2) a DNA molecule with the indicated sequence but which has undergone some degree of purification relative to the genome and may retain some number of immediately contiguous genomic sequences. For example, such molecules include those

present on an isolated restriction fragment or such molecules obtained by PCR amplification. DNA can be isolated and purified to any degree using methods well known in the art.

[0039] In accordance with the invention, the "isolated nucleic acid" may be inserted into or itself comprise a vector, such as a plasmid or virus vector, or be integrated into the genomic DNA of a prokaryote or eukaryote. With respect to RNA molecules of the invention, the term "isolated nucleic acid" primarily refers to an RNA molecule encoded by an isolated DNA molecule as defined above. But also includes RNA that has been isolated from a cellular source or RNA that has been chemically synthesized (and obtained at any level of purity). In these cases, the RNA molecule has been sufficiently separated from RNA molecules with which it would be associated in its natural state (*i.e.*, in cells or tissues), such that it exists in a purified pure form, e.g., that the RNA is enriched in the mixture relative to its abundance as naturally produced.

[0040] In a preferred embodiment, the isolated nucleic acid is an expression vector and has the sRNA sequence operably linked to a promoter or other regulatory sequences to control expression thereof. Expression vectors can encode one or more sRNAs and these can be coordinately or individually expressed, e.g., using one promoter or multiple promoters. Useful promoters and regulatory sequences for any of the expression vectors of the are well known to those of skill in the art.

[0041] Expression vectors are useful for any one of the following purposes: propagation of the sRNA, purification of the sRNA, or delivery and expression of the sRNA in a subject. Expression vectors can be used for any cell type, including bacterial, yeast, insect and mammalian systems, and include all types of vectors including viral vectors. Methods of making and using expression vectors, as well as selecting the appropriate host cell system are well known to those of skill in the art. Well-known promoters can be present, such as the lactose promoter system, a tryptophan (Trp) promoter system, a beta-lactamase promoter system, an arabinose-inducible promoter or a promoter system from phage lambda. The promoters typically control expression, optionally with an operator sequence and have ribosome binding site sequences for example, for initiating and completing transcription and translation. Among vectors preferred for use in bacteria include pQE70, pQE60 and pQE9, available from QIAGEN, Inc.; pBluescript vectors, Phagescript vectors, pNH8A, pNH16a, pNH18A, pNH46A, available from Stratagene Cloning Systems, Inc.; and ptrc99a, pKK223-3, pKK233-3,

pDR540, pRIT5 available from Pharmacia Biotech, Inc. Any expression vector is contemplated.

Vibrio Strains and Methods of Use

[0042] Another aspect of the present invention provides *Vibrio* strains having a deletion or mutation of one or more *qrr* genes. With *qrr* genes identified and sequenced, those of skill in the art can readily delete or mutate one or more *qrr* genes in a *Vibrio* strain of any genetic background. In a preferred aspect, any other gene or allele involved in quorum sensing can be present or absent in these strains. Examples of such genes, include but are not limited to *luxO*, *luxS*, *luxO* D47E (the "locked" strain), *hfq* and the like.

[0043] Mutants can be made by PCR mutagenesis, site-directed mutagenesis, allele replacement (Bassler *et al.* 1993) or any other methods known to those of skill in the art. *V. harveyi* deletions can be constructed, for example, using the method of Datsenko *et al.* (2000). As another example, in-frame deletions can be constructed by the method of Skorupski *et al.* (1996). The *qrr* gene deletions or mutations are introduced, constructed or are otherwise selected in any *Vibrio* species, including those listed elsewhere herein. The preferred species are *V. cholerae*, *V. parahaemolyticus*, *V. vulnificus* and/or *V. harveyi*.

[0044] Any number of *qrr* genes can be deleted or mutated in the strains of the invention, *i.e.*, single, double, triple, quadruple and quintuple (if applicable) mutants can be constructed. Examples of *V. cholerae* triple mutant strains include DL2998 ($\Delta qrr2$, $\Delta qrr3$, $\Delta qrr4$), DL2996 ($\Delta qrr1$, $\Delta qrr3$, $\Delta qrr4$) and DL2955 ($\Delta qrr1$, $\Delta qrr2$, $\Delta qrr4$), DL2997 ($\Delta qrr1$, $\Delta qrr2$, $\Delta qrr3$). Examples of *V. cholerae* quadruple mutants, *i.e.*, having no active *qrr* genes, include DL2956 ($\Delta qrr1$, $\Delta qrr2$, $\Delta qrr3$, $\Delta qrr4$), DL3024 (*luxO* D47E, $\Delta qrr1$, $\Delta qrr2$, $\Delta qrr3$, $\Delta qrr4$), DL2953 ($\Delta qrr1$, $\Delta qrr2$, $\Delta qrr3$, $\Delta qrr4$) and DL3020 (*luxO* D47E, $\Delta qrr1$, $\Delta qrr2$, $\Delta qrr3$, $\Delta qrr4$).

[0045] Such strains are useful in methods for identifying regulators of quorum sensing including, but not limited to, methods of identifying a quorum-sensing regulator by (a) contacting *Vibrio* cells having at least one inactive *qrr* gene with a test compound; (b) assaying a quorum sensing response of those cells to the test compound; and comparing those results with appropriate controls to determine whether or not the test compound is a quorum-sensing regulator. In preferred embodiments, the *Vibrio* strains have no more than one active *qrr* gene or no active *qrr* genes.

[0046] Assays for quorum-sensing responses can be measured by many different techniques and are well known in the art. For example, in a preferred method, the assay measures cell density-dependent changes in light production or in a reporter system. Assays can also measure expression of virulence genes, biofilm formation or expression of any other gene or gene product under control of the quorum sensing system.

[0047] The general use of reporter systems are well known to those of skill in the art. In the present assays, reporter systems can conveniently be used in conjunction with the *lux* promoter or another quorum-sensing promoter. In one set of preferred embodiments, the reporter system comprises the *V. harveyi lux* operon, a *lux* promoter operably linked to a reporter molecule or a quorum-sensing promoter operably linked to a reporter molecule. Any reporter molecule can be used, including those adaptable to high throughput screening techniques. Examples of reporter molecules include, but are not limited to, β -galactosidase, a green fluorescent protein (GFP) or any fluorescent variant derivative thereof, a luciferase, chloramphenicol acetyl transferase (CAT), β -glucuronidase (GUS), alkaline phosphatase and horseradish peroxidase. The majority of these reporters are commercially available. In a preferred embodiment, the *Vibrio* cells are *V. cholerae* comprising a *lux* operon or are *V. harveyi*. Such assays can also be conducted with any naturally bioluminescent *Vibrio*. By measuring bioluminescence, this assay can be readily adapted to high throughput screening methods.

[0048] When the *Vibrio* cells have one active *qrr* gene, this method is useful to identify activators of quorum sensing. when the *Vibrio* cells have no active *qrr* gene, this method is useful to identify inactivators of quorum sensing.

[0049] The quorum-sensing regulators identified by the above method can be used to promote or impede biofilm formation as well as to control virulence gene expression in pathogenic *Vibrio* species. Likewise, such regulators or their analogs, can be useful to control gene expression for systems influenced by quorum sensing in other bacterial species such as *Pseudomonas phosphoreum*, *Yersinia enterocolitica*, *E. coli*, *S. typhimurium*, *Salmonella typhi*, *Haemophilus influenzae*, *Helicobacter pylori*, *Bacillus subtilis*, *Borrelia burgdorferi*, *Neisseria meningitidis*, *Neisseria gonorrhoeae*, *Yersinia pestis*, *Campylobacter jejuni*, *Deinococcus radiodurans*, *Mycobacterium tuberculosis*, *Enterococcus faecalis*, *Streptococcus pneumoniae*, *Streptococcus pyogenes* and *Staphylococcus aureus*.

Hfq Nucleic Acids, Proteins and Antibodies

[0050] In another embodiment, the invention is directed to isolated nucleic acids encoding a *V. harveyi* or *V. cholerae* Hfq protein comprising an amino acid sequence of SEQ ID NOS. 39 and 41, respectively, conservative amino acid substitutions therein as well as those proteins and isolated antibodies specific for those proteins.

[0051] The *hfq* nucleic acids of the invention can be produced recombinantly (e.g., by PCR cloning) or chemically synthesized. The nucleotide sequences for the coding regions of the *V. harveyi* or *V. cholerae* *hfq* genes are shown in SEQ ID NOS. 40 and 42, respectively.

[0052] Hfq nucleic acids of the invention, or fragments thereof, may be used as probes for *hfq* genes in (1) *in situ* hybridization; (2) Southern hybridization (3) Northern hybridization; and (4) assorted amplification reactions such as polymerase chain reactions (PCR). They may also be used as probes to identify related genes from other bacteria, including other *Vibrio* species.

[0053] Hfq nucleic acids may further be used to produce large quantities of substantially pure encoded protein, or selected portions thereof, using techniques known in the art. In this regard, the cloned genes inserted into expression vectors can be used to make large quantities of the molecule itself in a recombinant host such as *E. coli* DH5 α . Large quantities of Hfq can be made through use of the cloned gene in an expression vector, and thereafter used in library screens for potential inhibitors targets in bioluminescence assays.

[0054] Purified Hfq, or fragments thereof, may be used to produce antibodies that also may serve as sensitive detection reagents for those proteins in cultured cells. Recombinant techniques enable expression of fusion proteins containing part or all of Hfq. The full length protein or fragments of the protein may be used to advantage to generate an array of antibodies specific for various epitopes of the protein, thereby providing even greater sensitivity for detection of the protein. Other uses of Hfq include overproduction to make a quantity sufficient for crystallization. Knowledge of the Hfq crystal structure would enable determination of Hfq sRNA binding site, and could therefore be used for computer-aided design of regulators of quorum sensing and for rational drug design.

[0055] Antibodies can be polyclonal, monoclonal, chimeric, humanized, or fragments thereof such as Fab, Fc, single chain Fvs and the like. Methods of making all

of the foregoing are well known in the art. Such antibodies can be raised using the intact Hfq as the immunogen or any fragment thereof large enough to confer Hfq-specificity to the resultant antibodies.

[0056] Antibodies specific for Hfq may be used in a variety of assays designed to detect and quantitate the protein. Such assays include, but are not limited to: (1) flow cytometric analysis; (2) immunochemical localization of Hfq in cells; and (3) immunoblot analysis (*e.g.*, dot blot, Western blot) of extracts from various cells and tissues. Additionally, as described above, antibodies can be used for purification of the proteins (*e.g.*, affinity column purification, immunoprecipitation).

Pharmaceutical Preparations

[0057] Quorum sensing regulators can be formulated as pharmaceutical compositions comprising one or more of those molecules together with a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical carriers are described in Gennaro *et al.*, (1995). In addition to the pharmacologically active agent, the compositions can contain suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically for delivery to the site of action. Suitable formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form, for example, water-soluble salts. In addition, suspensions of the active compounds, as appropriate in oily injection suspensions may be administered. Suitable lipophilic solvents or vehicles include fatty oils, for example, sesame oil or synthetic fatty acid esters, for example, ethyl oleate or triglycerides. Aqueous injection suspensions can contain substances which increase the viscosity of the suspension include, for example, sodium carboxymethyl cellulose, sorbitol, and dextran. Optionally, the suspension can also contain stabilizers. Liposomes can also be used to encapsulate the agent for delivery into the cell.

[0058] The pharmaceutical formulation for systemic administration according to the invention can be formulated for enteral, parenteral or topical administration. Indeed,

all three types of formulations can be used simultaneously to achieve systemic administration of the active ingredient.

[0059] Suitable formulations for oral administration include hard or soft gelatin capsules, pills, tablets, including coated tablets, elixirs, suspensions, syrups or inhalations and controlled release forms thereof.

[0060] Quorum sensing regulators can also be incorporated into pharmaceutical compositions which allow for the sustained delivery of those compounds to a mammal for a period of several days, to at least several weeks, to a month or more. Such formulations are described in U.S. Pat. Nos. 5,968,895 and 6,180,608 B1.

[0061] For topical administration, any common topical formation such as a solution, suspension, gel, ointment or salve and the like can be employed. Preparation of such topical formulations are well described in the art of pharmaceutical formulations as exemplified, for example, by Remington's Pharmaceutical Sciences. For topical application, Quorum sensing regulators can also be administered as a powder or spray, particularly in aerosol form. The active ingredient can be administered in pharmaceutical compositions adapted for systemic administration. As is known, if a drug is to be administered systemically, it can be confected as a powder, pill, tablet or the like or as a syrup or elixir for oral administration. For intravenous, intraperitoneal or intra-lesional administration, the active ingredient will be prepared as a solution or suspension capable of being administered by injection. In certain cases, it may be useful to formulate the active ingredient in suppository form or as an extended release formulation for deposit under the skin or intramuscular injection. In a one embodiment, quorum sensing regulators can be administered by inhalation. For inhalation therapy the compound can be in a solution useful for administration by metered dose inhalers or in a form suitable for a dry powder inhaler.

[0062] It will be appreciated by those skilled in the art that various omissions, additions and modifications may be made to the invention described above without departing from the scope of the invention, and all such modifications and changes are intended to fall within the scope of the invention, as defined by the appended claims. All references, patents, patent applications or other documents cited are herein incorporated by reference in their entirety.

EXAMPLE 1

Experimental Procedures**A. Bacterial Strains and Media**

[0063] *V. harveyi* strains are derived from BB120 (Bassler *et al.*, 1997) and were grown at 30°C with aeration in Luria-marine (LM), heart infusion (HI), or autoinducer bioassay (AB) broth (Bassler *et al.*, 1994b; Freeman *et al.*, 1999). *V. cholerae* strains are derivatives of El Tor strain C6706str2 (Thelin *et al.*, 1996) and were grown at 30°C with aeration in Luria-Bertani (LB) or SOC broth (Sambrook *et al.*, 1989). For studies of toxin coregulated pilus (TCP), *V. cholerae* was grown at 37°C in AKI medium under AKI conditions (Iwanaga *et al.*, 1986). *E. coli* S17-1 λ pir (de Lorenzo *et al.*, 1994) and JM109 (Yanisch-Perron *et al.*, 1985) were used to propagate plasmids at 37°C in LB. The following antibiotics were used: ampicillin (amp), 100 μ g/ml; tetracycline (tet), 10 μ g/ml; kanamycin (kan), 100 μ g/ml; chloramphenicol (cm), 10 μ g/ml; and gentamicin (gent), 100 μ g/ml. Streptomycin (strep) was used at 1 mg/ml and polymyxin B (pb) at 50 units/ml.

B. DNA Manipulations

[0064] All DNA manipulations were performed according to Sambrook *et al.* (1989). PFUTurbo[®] polymerase (Stratagene) was used for PCR reactions used in cloning, whereas Taq polymerase (Roche) was used for all other PCR reactions. dNTPs, restriction endonucleases, and T4 ligase were obtained from New England Biolabs. DNA purification kits were obtained from QIAGEN. *V. harveyi* deletions were constructed using the method of Datsenko and Wanner (2000). Constructions were placed on the *V. harveyi* chromosome by allele replacement (Bassler *et al.*, 1993). In-frame deletions were constructed by the method of Skorupski *et al.*, (1996). *hapR-lacZ* reporter fusions were constructed via the method of Kalogeraki *et al.*, (1997). *qrr1* from *V. cholerae* was overexpressed from plasmid pKK177-3RI (Brosius *et al.*, 1984). For *V. harveyi*, a kan resistance cassette was also incorporated into pKK177-3RI. The *qrr1-lux* transcriptional fusion plasmid was constructed by ligating a *PacI* fragment from pCS26-*Pac* (Bjarnason *et al.*, 2003) into an engineered *PacI* site in pBBR1MCS (Kovach *et al.*, 1994). The vector was digested with *Bam*HI, which eliminated a roughly 2 kb DNA fragment, and a PCR-amplified fragment containing the promoter region of *V. cholerae qrr1* was cloned into the *Bam*HI site.

C. Bioluminescence Assays

[0065] *V. harveyi* cultures were grown in AB broth for 14 hr at 30°C with aeration. The cultures were diluted 1:5000 prior to bioluminescence assays, which were performed as described (Bassler *et al.*, 1993). Relative light units for *V. harveyi* are defined as counts min⁻¹ ml⁻¹ x 10³/cfu ml⁻¹. *V. cholerae* bioluminescence assays were performed following 10 hr growth at 30°C in SOC containing tet to maintain the plasmid pBB1 carrying *V. harveyi luxCDABE*. OD_{600nm} for each culture was measured, and the cultures were diluted such that each culture was at the same cell density (~1:1000 dilution). Light and OD_{600nm} were measured every 45 min as described (Miller *et al.*, 2002). Relative light units for *V. cholerae* are defined as counts min⁻¹ ml⁻¹/OD_{600nm}.

D. β-Galactosidase Assays

[0066] β-galactosidase assays were performed in triplicate as described by Slauch *et al.*, (1991). β-galactosidase units are defined as [V_{max}][dilution factor]/OD_{600nm}.

E. Western Blot Analysis and Antibody Preparation

[0067] Western blot analysis was performed as described (Henke *et al.*, 2004), the membranes were exposed to anti-TcpA antibody, and chemiluminescence detection (Amersham) was used (Sun *et al.*, 1991). To analyze HapR and LuxR protein levels, HapR and LuxR were purified (Chen *et al.*, 2002b), and polyclonal antibodies were generated (Henke *et al.*, 2004). Polyclonal antisera were adsorbed to both *E. coli* pGEX-4T-1 lysates and either a *V. cholerae hapR* mutant lysate or a *V. harveyi luxR* mutant lysate prior to use.

F. Northern Blot Analysis

[0068] Cultures used for RNA preparations were grown to OD_{600nm} of 0.5. Rifampicin was added at 100 µg/ml, and each culture was further incubated with aeration at 30°C. Aliquots were taken at the appropriate times, and RNA was extracted with TRIzol[®] reagent (Invitrogen) and chloroform. TRIzol reagent is a monophasic solution of phenol and guanidine isothiocyanate. RNA was precipitated with isopropanol, washed with 75% ethanol, and resuspended in DEPC water. Northern blots were performed as described (Martin *et al.*, 1989). Steady-state Northern blots were performed as above except that no rifampicin was added.

G. Genetic Screen to Identify *hfq*

[0069] *V. harveyi* strain JAF548 (*luxO* D47E *kan*^r) was mutagenized with Mini-MulacZ (*cm*^r) as described (Martin *et al.*, 1989). Bright colonies were isolated, and insertions in *luxO* and *rpoN* were identified by PCR and complementation. Tn5*lacZ* mutagenesis of *hfq* in cosmid pBNL2014 was carried out as described previously (Showalter *et al.*, 1990). Transposon insertions were mapped by restriction analysis and sequencing. Cosmid pBNL2031, containing a Tn5*lacZ* insertion in *hfq*, was used in the allelic replacement procedure to generate BNL258 (*hfq*::Tn5*lacZ*).

EXAMPLE 2**A Genetic Screen for the *V. harveyi* Quorum-Sensing Repressor**

[0070] A previously characterized LuxO allele, *luxO* D47E, was used to identify the repressor that acts downstream of LuxO (Freeman *et al.*, 1999). The D47E mutation alters the site of phosphorylation, and “locks” the LuxO D47E protein into a state mimicking LuxO-P. The *V. harveyi luxO* D47E strain was mutagenized with the transposon Mini-MulacZ and screened for colonies that had acquired a bright phenotype, indicating that they had obtained a mutation bypassing the dark LuxO D47E phenotype.

[0071] Of the 40,000 transposon insertion mutants generated, 85 were bright. The majority of these (82) contained transposon insertions in either *luxO* or *rpoN*, the gene encoding σ^{54} . Three bright mutants did not harbor mutations in either of these genes. A *V. harveyi* genomic cosmid library was introduced into one of these mutants (BNL211) and screened for restoration of the dark phenotype. All cosmids conferring a dark phenotype contained overlapping regions of DNA, suggesting that a single locus was responsible. One cosmid, pBNL2014, was mutated with Tn5*lacZ* to pinpoint the region responsible for *lux* repression. The region identified was cloned and sequenced and found to contain the gene *hfq* (Fig. 2A). The *V. harveyi hfq* gene displays high homology to *hfq* genes from other *Vibrio* species, including *V. parahaemolyticus*, *V. cholerae*, and *V. vulnificus*, with 100%, 95%, and 94% identity, respectively using the NCBI Blast program. The GenBank accession number for the *V. harveyi hfq* locus is AY578785. The *V. harveyi hfq* coding region sequences are provided as SEQ ID NO. 39 for the amino acid sequence and as SEQ ID NO.40 for the nucleotide sequence. The same sequence information is provided in SEQ ID NOS. 41 and 42, respectively, for the *V. cholerae hfq* coding region.

EXAMPLE 3

Hfq Regulates Quorum Sensing

[0072] To verify that Hfq has a role in quorum-sensing regulation in *V. harveyi*, *hfq* null mutations were introduced onto the chromosomes of the *V. harveyi*, *hfq* wild-type and *luxO* D47E strains. The Lux phenotypes of the single *hfq* and double *luxO* D47E, *hfq* mutants were examined and compared to those of the wild-type, *luxO*, and *luxO* D47E *V. harveyi* strains (Fig. 2B). Wild-type *V. harveyi* displays typical quorum-sensing behavior (squares): it is very bright immediately following dilution into fresh medium, but, early in the assay, luminescence decreases precipitously (~1000-fold) due to dilution of the autoinducers to a level below that required for activation of *lux*. However, as the cells grow, endogenously produced autoinducers accumulate to the level required for detection. Light production commences and increases 1000-fold, ultimately reaching the predilution level. The *luxO* null strain (diamonds) is constitutively bright because, in the absence of LuxO, no *lux* repressor is produced. Conversely, the *luxO* D47E strain (open triangles) is dark. The *hfq* mutant (circles) has a phenotype indistinguishable from the *luxO* mutant, demonstrating that Hfq is required for repression of *lux* expression at low cell densities. The *luxO* D47E, *hfq* double mutant (closed triangles) is also constitutively bright, showing that repression of *lux* by Hfq occurs downstream of LuxO.

[0073] Hfq has the identical role in *V. cholerae* that it has in *V. harveyi* quorum sensing. Density-dependent light production from *V. cholerae* strains carrying *V. harveyi lux* was measured. The Lux phenotypes of the wild-type (squares), *luxO* (diamonds), *luxO* D47E (open triangles), *hfq* (circles), and *luxO* D47E, *hfq* (closed triangles) single and double *V. cholerae* mutants mimic the corresponding *V. harveyi* mutant phenotypes (Fig. 2C).

EXAMPLE 4

Hfq Regulates Virulence Gene Expression in *V. cholerae*

[0074] To show that the quorum-sensing activity of Hfq is not restricted to the nonnative *lux* target in *V. cholerae*, TcpA (the major subunit of the toxin-coregulated pilus) production was measured using Western blots (Fig. 2D) (Taylor, 1991). TcpA is present in the wild-type strain because, at low cell density, quorum sensing initiates the

cascade leading to TcpA production, which enables its detection at high cell density (Zhu *et al.*, 2002). No TcpA is observed in the *luxO* strain, because LuxO-P is required at low cell density to initiate the production of the TcpA observed in the wild-type. In contrast, high levels of TcpA are observed in the *luxO* D47E strain. Similarly, the *hapR* mutant that is also locked in low cell density mode produces high levels of TcpA. Low TcpA is detected in the *hfq* mutant, demonstrating that Hfq is required for virulence-factor expression. TcpA production in the double *luxO* D47E, *hfq* and *hapR*, *hfq* mutants demonstrates that Hfq acts downstream of LuxO and upstream of HapR in the quorum-sensing regulatory cascade.

EXAMPLE 5

Hfq Involvement in Quorum Sensing

[0075] In *E. coli* and other bacteria, Hfq binds a variety of small regulatory RNAs (sRNAs) and promotes interaction between the sRNAs and their target mRNAs (Masse *et al.*, 2003b; Valentin-Hansen *et al.*, 2004). These Hfq-sRNA complexes alter the stability/translation of the target mRNAs. The discovery that Hfq is required for quorum-sensing repression in *V. harveyi* and *V. cholerae* led to two predictions: first, quorum-sensing repression occurs posttranscriptionally, and, second, there must be one or more sRNAs involved. LuxO-P and σ^{54} do not control transcription of *hfq* further suggested that, at low cell density, the LuxO-P σ^{54} complex activates the transcription of the gene(s) encoding the sRNA(s).

A. Hfq Affects the Stability of *luxR*/*hapR* mRNA

[0076] LuxR and HapR appear to be the master regulators of their respective quorum-sensing regulons (Henke *et al.*, 2004; Zhu *et al.*, 2002).

[0077] Northern blots were used to determine the effect of *hfq* mutations on *luxR* and *hapR* mRNA stability in *V. harveyi* and *V. cholerae*. Rifampicin was added to cultures to terminate transcription, after which the *luxR* and *hapR* transcripts were monitored over time. The analysis was performed in *luxO* D47E strains to assess the fate of the *luxR* and *hapR* transcripts at low cell density. Fig. 3A shows that, under these conditions, both the *luxR* and *hapR* transcripts disappear immediately following termination of transcription (panels labeled *luxO* D47E). However, in the *luxO* D47E, *hfq* double mutants, the transcripts show significantly increased longevity (Fig. 3A, panels labeled *luxO* D47E, *hfq*). The control shows that mutation of *hfq* has no effect on the

stability of *rpsL* mRNA (Fig. 3A, four lower panels). Western blots show that the increased stability of the *luxR* and *hapR* mRNAs in the *hfq* mutants leads to increased levels of the LuxR and HapR proteins (Fig. 3B). These results demonstrate that, at low cell density, Hfq destabilizes the *luxR* and *hapR* mRNA in *V. harveyi* and *V. cholerae*, respectively, which leads to reduced LuxR and HapR protein in the cells.

B. LuxO-P Regulation of *hapR* Is Posttranscriptional and Requires Hfq

[0078] Previous analyses have suggested that LuxO-P controls transcription of *hapR* in *V. cholerae* (Zhu *et al.*, 2002). To distinguish between transcriptional and posttranscriptional regulation of *hapR*, chromosomal *hapR-lacZ* transcriptional, translational, and promoter fusions were constructed and their activities were measured in the *V. cholerae* wild-type, *luxO* D47E, *hfq*, and *luxO* D47E, *hfq* strains. The transcriptional and translational fusions are repressed in the *luxO* D47E strain, and repression requires Hfq (Figs. 4A and 4B, respectively). In contrast, *luxO* D47E does not repress the *hapR-lacZ* promoter fusion in which *lacZ* fused to the predicted site of transcription initiation (+1 site) (Fig. 4C). These results suggest that LuxO-P of *hapR* is posttranscriptional and show that region between the predicted +1 site and the *hapR* coding region is required for Hfq control.

EXAMPLE 6

Identification of sRNAs Involved in Quorum-Sensing Using Bioinformatics

[0079] The findings point toward a LuxO- σ^{54} -regulated sRNA in the quorum-sensing signal-transduction circuits of *V. harveyi* and *V. cholerae*. These small genes are very difficult to identify by traditional genetic approaches, so a method to scan the *V. cholerae* genome for candidate sRNA loci was developed. For this analysis, the following parameters were used: (1) the upstream region of the locus must contain a σ^{54} binding site; (2) since most sRNAs identified to date have Rho-independent terminators (Argaman *et al.*, 2001; Chen *et al.*, 2002a; Wassarman *et al.*, 2001), the presence of a Rho-independent terminator was required; (3) since most sRNAs are located in intergenic regions (Argaman *et al.*, 2001; Wassarman *et al.*, 2001), the search was restricted to regions between annotated genes; and (4) the sRNA must be conserved in *V. cholerae*, *V. parahaemolyticus*, and *V. vulnificus*. The completed genome sequences of these vibrios show that they possess homologs of *luxR/hapR*, *luxO*, *luxU*, and *hfq*, suggesting that they

have a conserved quorum-sensing regulatory mechanism (Chen *et al.*, 2003; Heidelberg *et al.*, 2000; Makino *et al.*, 2003).

[0080] Using PATSER, the *V. cholerae* genome was scanned for potential σ^{54} binding sites with a weight matrix constructed from a compiled set of ~180 σ^{54} binding sites from multiple bacterial species (Barrios *et al.*, 1999; Dombrecht *et al.*, 2002; Hertz *et al.*, 1999; van Helden, 2003). All hits above a cutoff score chosen to include all binding sites upstream of genes in *V. cholerae* that are known to be regulated by σ^{54} were considered. In a parallel procedure, the upstream regions of the known *V. cholerae* σ^{54} -regulated genes were extracted, and searched with the program CONSENSUS for a 16 bp motif (Hertz *et al.*, 1999). The motif so obtained corresponded perfectly to the known σ^{54} binding sites in *V. cholerae*, with the consensus sequence 5'-TGGCAC-N⁵-TTGCA/T-3' (SEQ ID NO. 43). The aligned set of binding sites was used to construct a weight matrix for σ^{54} sites specific to *V. cholerae*. The weight matrices obtained by these two procedures were quite similar and the final result did not depend on the weight matrix used to scan the genome.

[0081] The analysis of *V. cholerae* identified several predicted σ^{54} binding sites in intergenic regions. These regions were examined for conservation across the specified vibrio genomes and for the presence of Rho-independent terminators. These constraints narrowed the search to four intergenic regions. The sequences and alignment of these four regions are shown in Fig. 5A, along with the corresponding regions from *V. parahaemolyticus* and *V. vulnificus*. These four loci are highly homologous to one another. They all contain the signature σ^{54} binding site and a terminator, suggesting that these elements are independently transcribed loci. These loci were designated as *qrr1*, *qrr2*, *qrr3*, and *qrr4* (for quorum regulatory rna 1–4). Interestingly, one of the sRNA loci, *qrr1*, is located immediately upstream of *luxO*. In *V. parahaemolyticus* and *V. vulnificus*, a fifth putative sRNA locus was identified that fulfilled all of the search criteria (denoted *qrr5*).

[0082] The RNAFOLD program was used to find the predicted secondary structures of the candidate sRNAs (Fig. 5B) (Hofacker, 2003). The predicted structures of *Qrr2* and *Qrr3* are very similar, as is the structure of *Qrr4* if the three nucleotide pairs joining the two center loops are melted (and note these three nucleotide pairs are not conserved across species). Thus, only the predicted structure of *Qrr1* is obviously distinct. *Qrr2* and *Qrr3* show a site similar to the proposed Hfq binding site, which is an

8–12 nucleotide AU-rich region adjacent to stem loops (Moll *et al.*, 2003). The composition of the loops is variable across species, but the stems are highly conserved, supporting the folding predictions. Many small regulatory RNAs act by base pairing to complementary regions in the 5' untranslated region of the mRNA. Using the program LALIGN, which finds the best local alignment of the input sequences, the complement of the *hapR* untranslated upstream region was aligned with all four *V. cholerae* sRNAs and the *luxR* upstream region with *V. harveyi* Qrr1 (Fig. 5C and 5D, respectively).

Interestingly, the region identified as being potentially involved in the complementary base pairing is absolutely conserved among all four sRNA candidates, with a single base difference in *V. harveyi* qrr1 (Fig. 5A). The highly conserved region overlaps the *hapR* and *luxR* putative ribosome binding sites (AAGGAUUAU for *hapR* and AAGGAAAA for *luxR*). Finally, analysis of the upstream regions of *hapR* and *luxR* and their orthologs across all the sequenced vibrios indicates that this region of interaction with the sRNAs is strongly conserved.

EXAMPLE 7

LuxO-P- σ^{54} Controls the Expression of the sRNA Loci

[0083] It appears that the four putative sRNA loci in *V. cholerae*, and possibly five in *V. parahaemolyticus*, *V. vulnificus*, and *V. harveyi*, are regulated by LuxO-P together with σ^{54} . Analysis of the up-stream regions of the candidate sRNA loci shows a highly conserved region upstream of the σ^{54} site. This site has dyad symmetry, and the consensus sequence is TTGCAW₃TGCAA (where W corresponds to A/T; SEQ ID NO. 46).

[0084] To ascertain whether any of the candidate sRNA loci is a target of LuxO-P- σ^{54} regulation in *V. cholerae*, Northern blot analysis was used to quantify transcript levels. The DNA encoding the putative sRNAs was amplified by PCR and used to probe identical Northern blots containing RNA isolated from low cell density cultures of wild-type, *luxO*, *luxO* D47E, and *rpoN* *V. cholerae* strains. Fig. 6A (*hapR*⁺ panel) shows that, surprisingly, only Qrr4 is obviously regulated by LuxO-P- σ^{54} . A very small amount of this sRNA is detected in wild-type cells, whereas high levels are present in the *luxO* D47E strain. Importantly, Qrr4 is undetectable in both the *luxO* and *rpoN* mutants, consistent with a requirement for both LuxO-P and σ^{54} for activating the expression of the

locus encoding Qrr4 at low cell density. The other three *V. cholerae* sRNAs were not detected in this analysis.

[0085] Recently, it was shown in *E. coli* that, upon binding its mRNA target, the sRNA RyhB is degraded along with the target by RNaseE (Masse *et al.*, 2003a). In the absence of the mRNA targets, increased stability of RyhB is observed. Accordingly, it was possible that the Qrr sRNAs were being degraded along with the *hapR* target mRNA. To test this, *hapR* was deleted in the wild-type, *luxO*, *luxO* D47E, and *rpoN* *V. cholerae* strains and RNA was prepared. Northern blots were run and probed for all four sRNAs (Fig. 6A, *hapR*⁻ panel). In the absence of *hapR* mRNA, an increase in the level of Qrr4 is observed in the wild-type and *luxO* D47E strains. Minor amounts of Qrr2 and Qrr3 are also detected in the *luxO* D47E strain, showing that they are indeed regulated by LuxO-P and that their levels increase in the absence of *hapR* mRNA. However, the sRNA Qrr1 was not detected.

[0086] Additionally, *qrr1* resides up-stream of *luxO* in *V. harveyi* but was not detected by Northern blot (Fig. 6B). However, Qrr4 from *V. harveyi* was detected by probing total RNA with the DNA probe made from the *V. cholerae* *qrr4* PCR product, showing that such an sRNA exists in *V. harveyi*, and its expression is induced by LuxO D47E (Fig. 6B).

[0087] The inability to detect *V. cholerae* and *V. harveyi* Qrr1 could be a consequence of extremely low expression of *qrr1* or instability of the *qrr1* transcript, coupled with the insensitivity of the Northern blot procedure. Alternatively, expression of *qrr1* might not be controlled by LuxO-P; however, this seemed unlikely, based on the bioinformatics analysis. To eliminate this latter possibility, a *qrr1* transcriptional reporter was constructed by fusing the upstream region of *V. cholerae* *qrr1* to the *luxCDABE* (luciferase) operon and tested for the expression of the *qrr1-lux* fusion in the *luxO* null and *luxO* D47E *V. cholerae* strains. The presence of LuxO D47E causes a 220-fold increase in expression from the *qrr1* promoter, verifying that, indeed, *qrr1* is regulated by LuxO-P (Fig. 6C). It also seemed possible that the absence of the Qrr2-4 sRNAs might lead to enhanced expression of the remaining *qrr* gene, *qrr1*. However, no change in transcription of *qrr1-lux* occurred in the triple mutant, suggesting that the presence or absence of *qrr2-4* does not affect the expression of *qrr1*. Nevertheless, it appears that transcription of all four *qrr* genes is regulated by LuxO-P.

EXAMPLE 8

Four sRNAs Are Involved in Quorum-Sensing Repression in *V. cholerae*

[0088] To gain insight into the individual roles of the four sRNAs in quorum sensing, single, double, triple, and the quadruple *qrr* sRNA deletions were constructed in *V. cholerae* and density-dependent light production was measured. Only the simultaneous deletion of all four sRNAs affected bioluminescence expression (Fig. 7A). The results are shown for each triple mutant and the quadruple mutant. Single and double sRNA deletion mutants behaved similarly to the triple mutants. The results show that if any one of the four sRNAs is present, *V. cholerae* expresses density-dependent bioluminescence similar to the wild-type. However, deletion of all four sRNA genes together results in a constitutive *lux* phenotype identical to the *luxO* null mutant. Thus, all four sRNAs participate in quorum-sensing repression, although any one alone is sufficient.

[0089] Because deletion of the sRNAs eliminates quorum-sensing repression in *V. cholerae*, it follows that overexpression of the sRNAs should result in constitutive repression. This possibility was tested by overexpressing *V. cholerae qrr1* in various *V. cholerae* and *V. harveyi* strains and examining the impact on light production. Compared to the vector-alone control, when *V. cholerae qrr1* is overexpressed in *V. cholerae*, light production is reduced to 21% in the wild-type, 10% in the *luxO* null strain, and 1% in the quadruple sRNA mutant. Overexpression of *V. cholerae qrr1* in *V. harveyi* reduces light production to 12% in the wild-type and to 3% in the *luxO* null strain. Thus, the *V. cholerae* sRNA Qrr1 functions in both *V. cholerae* and *V. harveyi* to repress quorum sensing.

[0090] The data presented herein suggests that multiple sRNAs act downstream of LuxO-P to destabilize *luxR/hapR* mRNA and regulate quorum-sensing dependent gene expression in *V. harveyi* and *V. cholerae*. To verify this model, an epistasis test was performed in *V. cholerae*. For this test, light production and HapR and TcpA protein levels were measured in the *V. cholerae* wild-type strain, the *luxO* null mutant, the *luxO* D47E mutant, the quadruple sRNA deletion mutant, and the *luxO* D47E mutant containing the quadruple deletion of the *qrr* genes (Fig. 7B). Maximal light is produced and a corresponding high level of HapR protein is observed in the high cell density wild-type and *luxO* strains. Both light and HapR protein levels are severely reduced in the

luxO D47E strain. However, deletion of the four sRNAs alone or in the *luxO* D47E background restores maximal light production and maximal HapR protein production, showing that the four sRNAs are required for repression and act downstream of LuxO. Because *lux* and *tcpA* are regulated in an opposite manner by quorum sensing, TcpA levels are expected to vary reciprocally with those of *lux* expression and HapR concentration in the quorum-sensing mutants. Fig. 7B shows this is the case and that the four sRNAs are epistatic to LuxO-P in regulation of *tcpA*.

EXAMPLE 9

Regulatory Kinetics Model

[0091] Why does LuxO regulate *hapR/luxR* via sRNAs rather than directly? One reason may be that the sRNAs allow a simple “inversion” of regulatory control, so that the activator LuxO can repress *hapR/luxR*. However, this inversion could also be accomplished in other ways, e.g., by switching the regulation pattern of *hapR/luxR* with respect to its target genes. A more fundamental motivation for control via sRNAs may be to achieve an ultrasensitive (switchlike) response to the level of LuxO-P. As base pairing of an sRNA with its target message is known to promote degradation of both the sRNA and the message, this “mutual destruction” provides an elegant mechanism for ultrasensitivity. Specifically, as shown in Fig. 8, if the rate of synthesis of a particular sRNA exceeds the rate of synthesis of its target message, even if only slightly, then the sRNA can accumulate in the cell, and target message levels can be reduced to very low levels. In contrast, if the rate of synthesis of a particular target message exceeds that of its regulatory sRNA, then the message can accumulate (Fig. 8). The ultrasensitive mechanism described here also applies in the case of multiple sRNAs interacting with one or more mRNA targets (Paulsson *et al.*, 2001).

[0092] The use of sRNAs to accomplish an ultrasensitive response may be particularly apt for processes such as quorum sensing in which an all-or-nothing response is indicated. Similarly, this all-or-nothing requirement could explain why sRNAs control the entry into stationary phase. A different kind of sRNA switch was highlighted by Masse *et al.* (2003a) for the RyhB system. In this case, the sRNA RyhB was shown to mediate a rapid, reversible switch in time in response to a *large* change in input (e.g., addition of iron to the medium). In the quorum-sensing circuit, by contrast, the switch occurs in response to a *small* change in input (e.g., LuxO-P levels) that is strongly

amplified into a transition between two discrete states (e.g., low and high cell density). How fast this switch occurs in time will depend on the rate of change of LuxO-P levels as well as on the rate of accumulation and/or degradation of *luxR/hapR* mRNA and LuxR/HapR protein. Interestingly, an ultrasensitive response to LuxO-P via the rate of sRNA production puts a premium on precisely controlling the transcription rate of the sRNAs, consistent with the hypothesis that the presence of multiple sRNAs represents a mechanism for fine tuning the transition between low and high cell density states.

References

- [0093] Argaman *et al.* (2001) *Curr. Biol.* 11, 941–950.
- [0094] Barrios *et al.* (1999) *Nucleic Acids Res.* 27, 4305–4313.
- [0095] Bassler *et al.* (1993) *Mol. Microbiol.* 9, 773–786.
- [0096] Bassler *et al.* (1994a) *Mol. Microbiol.* 13, 273–286.
- [0097] Bassler *et al.* (1994b) *Mol. Microbiol.* 12, 403–412.
- [0098] Bassler *et al.* (1997) *J. Bacteriol.* 179, 4043–4045.
- [0099] Benson *et al.* (1994) *Proc. Natl. Acad. Sci. USA* 91, 4989–4993.
- [00100] Bjarnason *et al.* (2003) *J. Bacteriol.* 185, 4973–4982.
- [00101] Brosius *et al.* (1984) *Proc. Natl. Acad. Sci. USA* 81:6929–6933.
- [00102] Cao *et al.* (1989) *J. Biol. Chem.* 264, 21670–21676.
- [00103] Chen *et al.* (2002a) *Biosystems* 65, 157–177.
- [00104] Chen *et al.* (2002b) *Nature* 415, 545–549.
- [00105] Chen *et al.* (2003) *Genome Res.* 13, 2577–2587.
- [00106] Datsenko *et al.* (2000) *Proc. Natl. Acad. Sci. USA* 97, 6640–6645.
- [00107] de Lorenzo *et al.* (1994) *Methods Enzymol.* 235, 386–405.
- [00108] Dombrecht *et al.* (2002) *Genome Biol* 3. Published online November 26, 2002. RESEARCH0076.1–0076.11.
- [00109] Elf *et al.* (2003) *Biophys. J.* 84, 154–170.
- [00110] Federle *et al.* (2003) *J. Clin. Invest.* 112, 1291–1299.
- [00111] Freeman *et al.* (1999) *Mol. Microbiol.* 31, 665–677.
- [00112] Freeman *et al.* (2000a) *J. Bacteriol.* 181, 899–906.
- [00113] Freeman *et al.* (2000b) *Mol. Microbiol.* 35, 139–149.
- [00114] Fuqua *et al.* (2001) *Annu. Rev. Genet.* 35, 439–468.

- [00115] Gennaro *et al.*, (1995) Remington's Pharmaceutical Sciences, Mack Publishing Company.
- [00116] Gouet *et al.* (1999) *Bioinformatics* 15, 305–308.
- [00117] Hammer *et al.* (2003) *Mol. Microbiol.* 50, 101–104.
- [00118] Heidelberg *et al.* (2000) *Nature* 406, 477–483.
- [00119] Henke *et al.* (2004) *J. Bacteriol.*, in press. **[do you have this site?]**
- [00120] Hertz *et al.* (1999) *Bioinformatics* 15, 563–577.
- [00121] Hofacker (2003) *Nucleic Acids Res.* 31, 3429–3431.
- [00122] Iwanaga (1986) *Microbiol. Immunol.* 30, 1075–1083.
- [00123] Jobling *et al.* (1997) *Mol. Microbiol.* 26, 1023–1034.
- [00124] Kalogeraki *et al.* (1997) *Gene* 188, 69–75.
- [00125] Kovach *et al.* (1994) *Biotechniques* 16, 800–802.
- [00126] Kovacicova *et al.* (2002) *Mol. Microbiol.* 46, 1135–1147.
- [00127] Lilley *et al.* (2000) *Mol. Microbiol.* 36, 940–954.
- [00128] Makino *et al.* (2003) *Lancet* 361, 743–749.
- [00129] Martin *et al.* (1989) *J. Bacteriol.* 171, 2406–2414.
- [00130] Masse *et al.* (2003a) *Genes Dev.* 17, 2374–2383.
- [00131] Masse *et al.* (2003b) *Curr. Opin. Microbiol.* 6, 120–124.
- [00132] Miller *et al.* (2001) *Annu. Rev. Microbiol.* 55, 165–199.
- [00133] Miller *et al.* (2002) *Cell* 110, 303–314.
- [00134] Miyamoto *et al.* (1994) *Mol. Microbiol.* 14, 255–262.
- [00135] Mok *et al.* (2003) *EMBO J.* 22, 870–881.
- [00136] Moll *et al.* (2003) *RNA* 9, 1308–1314.
- [00137] North *et al.* (1996) *J. Mol. Biol.* 260, 317–331.
- [00138] Paulsson *et al.* (2001) *Q. Rev. Biophys.* 34, 1–59.
- [00139] Reitze *et al.* (1985) *Proc. Natl. Acad. Sci. USA* 82, 1979–1983.
- [00140] Sambrook *et al.* (1989) *Molecular Cloning: A Laboratory Manual* (Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press).
- [00141] Showalter *et al.* (1990) *J. Bacteriol.* 172, 2946–2954.
- [00142] Skorupski *et al.* (1996) *Gene* 169, 47–52.
- [00143] Slauch *et al.* (1991) *J. Bacteriol.* 173, 4039–4048.
- [00144] Sun, *et al.* (1991) *Infect. Immun.* 59, 114–118.
- [00145] Surette *et al.* (1999) *Proc. Natl. Acad. Sci. USA* 96, 1639–1644.

- [00146] Taylor (1991) *J. Chemother. Suppl.* 1 3, 190–195.
- [00147] Thelin *et al.* (1996) *Infect. Immun.* 64, 2853–2856.
- [00148] Thompson *et al.* (1994) *Nucleic Acids Res.* 22, 4673–4680.
- [00149] Valentin-Hansen *et al.* (2004) *Mol. Microbiol.* 51, 1525–1533.
- [00150] Vance *et al.* (2003) *Infect. Immun.* 71, 2571–2576.
- [00151] van Helden (2003). *Nucleic Acids Res.* 31, 3593–3596.
- [00152] Wassarman *et al.* (2001) *Genes Dev.* 15, 1637–1651.
- [00153] Wingrove *et al.* (1994) *Genes Dev.* 8, 1839–1852.
- [00154] Wu *et al.* (1997) *Mol. Microbiol.* 24, 233–239.
- [00155] Xavier *et al.* (2003) *Curr. Opin. Microbiol.* 6, 191–197.
- [00156] Yanisch-Perron *et al.* (1985) *Gene* 33, 103–119.
- [00157] Zhu *et al.* (2003) *Dev. Cell* 5, 647–656.
- [00158] Zhu *et al.* (2002) *Proc. Natl. Acad. Sci. USA* 99, 3129–3134.

WE CLAIM:

1. An isolated nucleic acid which comprises a nucleotide sequence encoding a small, regulatory RNA (sRNA) from a *Vibrio* species, wherein said sRNA interacts with a *Vibrio cholerae* Hfq protein or with the corresponding protein from said *Vibrio* species; said sRNA has a sequence sufficiently complementary to stably bind to a *V. cholerae* *hapR* mRNA or to the corresponding mRNA from said *Vibrio* species; said sRNA is encoded by a gene under control of a *V. cholerae* transcription factor sigma 54 (σ^{54}) or the corresponding transcription factor from said *Vibrio* species, of a *V. cholerae* LuxO protein or the corresponding protein from said *Vibrio* species, and of a Rho-independent terminator; and said sRNA is sufficient to regulate quorum sensing in one or more *Vibrio* species.
2. The isolated nucleic acid of Claim 1, wherein said gene is encoded in an intergenic locus of the genome of said *Vibrio* species.
3. The isolated nucleic acid of Claim 1, wherein said nucleic acid is RNA, DNA, stabilized RNA or stabilized DNA.
4. The isolated nucleic acid of Claim 1, wherein said nucleic acid is double stranded or single stranded.
5. The isolated nucleic acid of Claim 1, wherein said nucleic acid is an expression vector and said nucleotide sequence is operably linked to a promoter.
6. The isolated nucleic acid of Claim 4, wherein said promoter is an inducible promoter.
7. The isolated nucleic acid of Claim 1, wherein said *Vibrio* species is selected from the group consisting of *V. cholerae*, *V. parahaemolyticus*, *V. vulnificus* and *V. harveyi*.
8. The isolated nucleic acid of Claim 1, wherein said gene encodes is *qrr1*, *qrr2*, *qrr3* or *qrr4* from any one of *V. cholerae*, *V. parahaemolyticus*, *V. vulnificus* and *V. harveyi* or is *qrr5* from any one of *V. parahaemolyticus*, *V. vulnificus* and *V. harveyi*.
9. The isolated nucleic acid of Claim 1, wherein said nucleotide sequence is a DNA sequence selected from the group consisting of SEQ ID NO. 1-19 or a complement thereof.
10. The isolated nucleic acid of Claim 1, wherein said nucleic acid encodes an sRNA capable of hybridizing to a nucleotide sequence comprising SEQ ID NO. 1-19 under stringent hybridization conditions, said conditions including hybridizing in 6xSSC

at about 45°C followed by one or more washes in 0.1xSSC/0.2% SDS at about 68°C, or equivalently stringent hybridization conditions.

11. The isolated nucleic acid of Claim 1, wherein said nucleotide sequence is an RNA sequence selected from the group consisting of SEQ ID NO. 20-38.
12. An expression vector comprising one or more sRNAs of Claim 1.
13. An isolated *Vibrio* strain comprising a deletion or mutation of one or more *qrr* genes.
14. The strain of Claim 13, wherein said strain is from a *Vibrio* species selected from the group consisting of *V. cholerae*, *V. parahaemolyticus*, *V. vulnificus* and *V. harveyi*.
15. The strain of Claim 14, wherein all but one of said *qrr* genes is deleted or mutated.
16. The strain of Claim 15, wherein said strain is DL2998, DL2996, DL2955 or DL2997.
17. The strain of Claim 13, wherein all the *qrr* genes in said strain are deleted or mutated.
18. The strain of Claim 17, wherein said strain is DL2956, DL3024, DL2953 or DL3020.
19. An isolated nucleic acid which comprises a nucleotide sequence encoding a *V. harveyi* Hfq protein comprising an amino acid sequence of SEQ ID NO. 39 or a conservative amino acid substitution therein.
20. The isolated nucleic acid of Claim 20, wherein said nucleotide sequence comprises SEQ ID NO. 40.
21. A *V. harveyi* Hfq protein encoded by the nucleic acid of Claim 19.
22. An isolated antibody against the *V. harveyi* Hfq protein of Claim 21.
23. An isolated nucleic acid which comprises a nucleotide sequence encoding a *V. cholerae* Hfq protein comprising an amino acid sequence of SEQ ID NO. 41 or a conservative amino acid substitution therein.
24. The isolated nucleic acid of Claim 20, wherein said nucleotide sequence comprises SEQ ID NO. 42.
25. A *V. cholerae* Hfq protein encoded by the nucleic acid of Claim 23.
26. An isolated antibody against the *V. cholerae* Hfq protein of Claim 25.

27. A method of identifying a quorum-sensing regulator which comprises
- (a) contacting *Vibrio* cells comprising at least one inactivated *qrr* gene with a test compound;
 - (b) assaying a quorum sensing response to said compound; and
 - (c) determining whether said test compound is a quorum-sensing regulator.
28. The method of Claim 27, wherein said *Vibrio* cells comprise no more than one active *qrr* gene.
29. The method of Claim 28, wherein assaying a quorum sensing response is measuring cell density-dependent changes of a reporter system.
30. The method of Claim 29, wherein said reporter system comprises the *V. harveyi lux* operon, a *lux* promoter operably linked to a reporter molecule or a quorum-sensing promoter operably linked to a reporter molecule.
31. The method of Claim 29, wherein said reporter molecule is β -galactosidase, a green fluorescent protein or a fluorescent variant derivative thereof, a luciferase, chloramphenicol acetyl transferase, β -glucuronidase, alkaline phosphatase and horseradish peroxidase.
32. The method of Claim 28, wherein said *Vibrio* is *V. cholerae* comprising a *lux* operon or is *V. harveyi*.
33. The method of Claim 28, wherein said *Vibrio* cells comprise one active *qrr* gene and said method identifies activators of quorum sensing.
34. The method of Claim 28, wherein said *Vibrio* cells comprise no active *qrr* gene and said method identifies inactivators of quorum sensing.

1/16




FIG. 1A

2/16




FIG.1B




FIG.2A




FIG.2B




FIG.2C

4/16




FIG.2D




FIG.3A




FIG.3B

6/16




FIG.4A




FIG.4B




FIG.4C




FIG.5A-1

V. cholerae rrr1 [VC1020/VC1021]
V. cholerae rrr2 [VCA0040/VCA0041]
V. cholerae rrr3 [VCA0826/VCA0827]
V. cholerae rrr4 [VCA0958/VCA0959]
V. parahaemolyticus rrr1 [VP2099/VP2100]
V. parahaemolyticus rrr2 [VPA1623/VPA1624]
V. parahaemolyticus rrr3 [VPA1240/VPA1241]
V. parahaemolyticus rrr4 [VPA0199/VPA0200]
V. parahaemolyticus rrr5 [VPA0752/VPA0753]
V. vulnificus rrr1 [VW13091/VW13092]
V. vulnificus rrr2 [VW21243/VW21244]
V. vulnificus rrr3 [VW20786/VW20787]
V. vulnificus rrr4 [VW21645/VW21646]
V. vulnificus rrr5 [VW20047/VW20048]
V. harveyi rrr1

	Terminator
<i>V. cholerae</i> qrr1 [VC1020/VC1021]	TAGTGAATAATCA.ATGTTACAA...ATAAC...AGCCAAATAGACTCATTCT...ATTGGCTATTTTT
<i>V. cholerae</i> qrr2 [VCA0040/VCA0041]	TAGTGAATA..GTATTTGTTACATCAATATATA...AGCCAAATCGCG.GTTCTT.GCGAATTGGCTATTTTT
<i>V. cholerae</i> qrr3 [VCA0826/VCA0827]	TAGTGAATG...AAATTTGTTACAT..TTGTTTTATCAAGCCAAATCAC..CCTTTT.GTGAATTGGCTTTTT...
<i>V. cholerae</i> qrr4 [VCA0958/VCA0959]	TAGTGAACA.CCA.TTGTTCACAC..TTATAGA..CGGCCAAATCACA..CTTCTT.GTGGTTGGCCTTTTTTTT
<i>V. parahaemolyticus</i> qrr1 [VP2099/VP2100]	TAGTGAACG...ATAATGTTACAA...AACA...AGCCAAATAGAC..CCGACTGCCTATTGGCTCTTTTTTT
<i>V. parahaemolyticus</i> qrr2 [VPA1623/VPA1624]	TAGTGAATA.TAGATTGTTACAAATAAATATG...AGCCAAATCGCGATTATT..GCGGTTGGCTATTTTT.
<i>V. parahaemolyticus</i> qrr3 [VPA1240/VPA1241]	TAGTGAACCTTGATTTTGTTACAT.GTATATA...AGCCAAATCGCA..CTCTTT.GCGGTTGGCTATTTTT.
<i>V. parahaemolyticus</i> qrr4 [VPA0199/VPA0200]	TAGTGAATA.CACATTGTTACAA.GTATATA..CGGCCAAATCACC..TTTCTT.GTGAATTGGCGTTTTT..
<i>V. parahaemolyticus</i> qrr5 [VPA0752/VPA0753]	TAGTGAACC.CAA.TTGTTCACAA.GTATATA..CAGCCAAATCACA.CACCTT.GTGGTTGGCTTTTTTTT.
<i>V. vulnificus</i> qrr1 [VV13091/VV13092]	TAGTGAACC...TAGTGTTCACAA...TTGAT...AGCCAAATAG...TGAAATGACTGTTGGCTTTTTTTT.
<i>V. vulnificus</i> qrr2 [VV21243/VV21244]	TAGTGAATA.CACATTGTTACATCAATACATA...AGCCAAATCGGACTTATTTGCGGTTGGTTTTT....
<i>V. vulnificus</i> qrr3 [VV20786/VV20787]	TAGTGAACCT.TGATTGTTACAT.GTATATA...AGCCAAATCGCA..CCTTTT.GCGGTTGGCTCTTTTTT.
<i>V. vulnificus</i> qrr4 [VV21645/VV21646]	TAGTGAATAATGACTTTGTTACAC..ATATATA..CGGCCAAACAC..CTGATT.GTGTTTGGCCTTTTTT..
<i>V. vulnificus</i> qrr5 [VV20047/VV20048]	TAGTGAACC.TGA.TTGTTCACAA..ATATATA..CAGCCAAATCACCTCTTATT.GTGAATTGGCTTTTTT..
<i>V. harveyi</i> qrr1	TAGTGAACG...ACAATGTTACAG...AACG...AGCCAAATAGAT.CCGACTGCCTATTGGCTCTTTTTT

FIG.5A-2

10/16



FIG. 5B-2





FIG.5C



FIG.5D

12/16



13/16





FIG.6C



OD_{600nm}

FIG.7A

15/16




FIG.7B




FIG.8

SEQUENCE LISTING

<110> THE TRUSTEES OF PRINCETON UNIVERSITY

<120> SMALL RNAS AND BACTERIAL STRAINS INVOLVED IN QUORUM
SENSING

<130> Y2098-10476

<140>

<141>

<150> 60/561,660

<151> 2004-04-12

<160> 46

<170> PatentIn Ver. 3.3

<210> 1

<211> 96

<212> DNA

<213> *Vibrio cholerae*

<400> 1

tgacccgcaa gggtcaccta gccaaactgac gttgttagtg aataatcaat gttcacaaat 60
aacagccaat agactcattc tattggctat tttttt 96

<210> 2

<211> 108

<212> DNA

<213> *Vibrio cholerae*

<400> 2

tgacccttgt taagccgagg gtcacctagc caactgacgt tgttagtga tagtattgtt 60
cacatcatat ataagccaat cgcggttctt gcgattggct attttttt 108

<210> 3

<211> 107

<212> DNA

<213> *Vibrio cholerae*

<400> 3

tgacccttaa ttaagccgag ggtcacctag ccaactgacg ttgttagtga atgaaattgt 60
tcacatttgt tttatcagcc aatcaccctt ttgtgattgg cttttttt 107

<210> 4

<211> 107

<212> DNA

<213> *Vibrio cholerae*

<400> 4

tgacccttct aagccgaggg tcacctagcc aactgacgtt gttagtgaac accattgttc 60
acacttatag acggccaatc acacttcttg tgggtggcct tttttttt 107

<210> 5

<211> 95

<212> DNA

<213> *Vibrio harveyi*

<400> 5

ggacccctcg ggtcacctat ccaactgacg ttgttagtga acgacatgtt cacagaacga 60
gccaatagat ccgactgcct attggcttct ttttt 95

<210> 6

<211> 109

<212> DNA

<213> *Vibrio harveyi*

<400> 6

cgacccttct taagccgagg gtcacctagc caactgacgt tgtagtgaa tacacattgt 60
tcacaaaata cataagccaa tcgccctaatt tgcggttggc tttttttt 109

<210> 7

<211> 108

<212> DNA

<213> *Vibrio harveyi*

<400> 7

tgacccttct taagccgagg gtcacctagc caactgacgt tgtagtgga ctogaatttg 60
ttcacaaaata tataagccaa tcgcacaaat tgcggttggc tttttttt 108

<210> 8

<211> 107

<212> DNA

<213> *Vibrio harveyi*

<400> 8

agacccttat taagccgagg gtcacctagc caactgacgt tgtagtgaa tacacattgt 60
tcacaagtat ataccgcaa tcaactttat tgtgattggc gtttttt 107

<210> 9

<211> 106

<212> DNA

<213> *Vibrio harveyi*

<400> 9

tgaccctttt aagccgaggg tcacctagcc aactgacgtt gtagtgaa ccaattgttc 60
acacgtatat acagccaatc acaaaccttg tggttggcta tttttt 106

<210> 10

<211> 95

<212> DNA

<213> *Vibrio parahaemolyticus*

<400> 10

cgacccctcg ggtcacctag ccaactgacg ttgttagtga acgatatgtt cacaaaacaa 60
gccaatagac ccgactgcct attggcttct ttttt 95

<210> 11

<211> 108

<212> DNA

<213> *Vibrio parahaemolyticus*

<400> 11

cgacccttct taagccgagg gtcacctagc caactgacgt tgttagttaa tatagattgt 60
tcacaataaa tatgagccaa tcgcgattat tgcggttggc tttttttt 108

<210> 12

<211> 108

<212> DNA

<213> *Vibrio parahaemolyticus*

<400> 12

tgacccttct taagccgagg gtcacctagc caactgacgt tgttagttaa cttgattttg 60
ttcacatgta tataagccaa tcgcactctt tgcggttggc tttttttt 108

<210> 13

<211> 107

<212> DNA

<213> *Vibrio parahaemolyticus*

<400> 13

tgacccttat taagccgagg gtcacctagc caactgacgt tgttagttaa tacacattgt 60
tcacaagtat ataccgcaa tcaccttctt tgtgattggc gttttttt 107

<210> 14

<211> 107

<212> DNA

<213> *Vibrio parahaemolyticus*

<400> 14

tgaccctttc taagccgagg gtcacctagc caactgacgt tgttagttaa cccaattggt 60
cacaagtata tacagccaat cacacacctt gtggttggct tttttttt 107

<210> 15

<211> 93

<212> DNA

<213> *Vibrio vulnificus*

<400> 15

tgacccttcg ggtcacctag ccaactgacg ttgttagtga acctagtgtt cacaattgat 60
agccaatagt gaaatgactg ttggcttttt ttt 93

<210> 16

<211> 110

<212> DNA

<213> *Vibrio vulnificus*

<400> 16

cgacccttat taagccgagg gtcacctagc caactgacgt tgttagttaa tacacattgt 60
tcacatcata cataagccaa tcgcacttat tttgcggttg gttttttttt 110

<210> 17

<211> 108

<212> DNA

<213> *Vibrio vulnificus*

<400> 17
tgacccttat taagccgagg gtcacctagc caactgacgt tgtagtgaa cttgatttgt 60
tcacatgtat ataagccaat cgcacctttt gcggttggc cttttttt 108

<210> 18
<211> 107
<212> DNA
<213> *Vibrio vulnificus*

<400> 18
tgacccttat taagccgagg gtcacctagc caactgacgt tgtagtgaa taatgacttg 60
ttcacacata tatacggcca aacacctgat tgtgtttggc cttttttt 107

<210> 19
<211> 108
<212> DNA
<213> *Vibrio vulnificus*

<400> 19
tgaccctttt taagccgagg gtcacctagc caactgacgt tgtagtgaa cctgattgtt 60
cacaaatata tacagccaat cacctcttat tgtgattggc tttttttt 108

<210> 20
<211> 96
<212> RNA
<213> *Vibrio cholerae*

<400> 20
ugacccgcaa gggucaccua gccaacugac guuguuagug auaaucaau guucacaaau 60
aacagccaau agacucauuc uauuggcuau uuuuuu 96

<210> 21
<211> 108
<212> RNA
<213> *Vibrio cholerae*

<400> 21
ugacccuugu uaagccgagg gucaccuagc caacugacgu uguuagugaa uaguauuguu 60
cacaucuuau auaagccaau cgcgguucuu gcgauuggcu auuuuuuu 108

<210> 22
<211> 107
<212> RNA
<213> *Vibrio cholerae*

<400> 22
ugacccuuua uuaagccgag ggucaccuag ccaacugacg uguuaguga augaaaugu 60
ucacauuugu uuuaucagcc aaucacccuu uugugauugg cuuuuuuu 107

<210> 23
<211> 107
<212> RNA
<213> *Vibrio cholerae*

<400> 23

ugacccuucu aagccgaggg ucaccuagcc aacugacguu guuagugaac accauuguuc 60
acacuuauag acggccaau acacuucuuug ugguuggccu uuuuuuu 107

<210> 24

<211> 95

<212> RNA

<213> *Vibrio harveyi*

<400> 24

ggacccucg ggucaccuau ccaacugacg uuguuaguga acgacauguu cacagaacga 60
gccaaauagau ccgacugccu auuggcuucu uuuuu 95

<210> 25

<211> 109

<212> RNA

<213> *Vibrio harveyi*

<400> 25

cgacccuucu uaagccgagg gucaccuagc caacugacgu uguuagugaa uacacauugu 60
ucacaaaaua cauaagccaa ucgcccuaau ugcggguuggc uauuuuuuu 109

<210> 26

<211> 108

<212> RNA

<213> *Vibrio harveyi*

<400> 26

ugacccuucu uaagccgagg gucaccuagc caacugacgu uguuagugaa cucgaauuug 60
uucacaaaaua uauaagccaa ugcgacaaau ugcggguuggc uauuuuuuu 108

<210> 27

<211> 107

<212> RNA

<213> *Vibrio harveyi*

<400> 27

agacccuuau uaagccgagg gucaccuagc caacugacgu uguuagugaa uacacauugu 60
ucacaaguau auaccgcca ucaacuuaau ugugaauuggc guuuuuu 107

<210> 28

<211> 106

<212> RNA

<213> *Vibrio harveyi*

<400> 28

ugacccuuuu aagccgaggg ucaccuagcc aacugacguu guuagugaac ccaauuguuc 60
acacguauau acagccaau acaaaccuug ugguuggcua uuuuuu 106

<210> 29

<211> 95

<212> RNA

<213> *Vibrio parahaemolyticus*

<400> 29

cgacccucg ggucaccuag ccaacugacg uuguuaguga acgauauguu cacaaaacaa 60
gccaaauagac ccgacugccu auuggcuuuu uuuuu 95

<210> 30
<211> 108
<212> RNA
<213> *Vibrio parahaemolyticus*

<400> 30
cgacccuucu uaagccgagg gucaccuagc caacugacgu uguuagugaa uauagauugu 60
ucacaauaaa uaugagccaa ucgcgauuau ugcgguuggc uauuuuuu 108

<210> 31
<211> 108
<212> RNA
<213> *Vibrio parahaemolyticus*

<400> 31
ugacccuucu uaagccgagg gucaccuagc caacugacgu uguuagugaa cuugauuuug 60
uucacaugua uauaagccaa ucgcacucuu ugcgguuggc uauuuuuu 108

<210> 32
<211> 107
<212> RNA
<213> *Vibrio parahaemolyticus*

<400> 32
ugacccuuau uaagccgagg gucaccuagc caacugacgu uguuagugaa uacacauugu 60
ucacaaguau auaccgcca uacccuuucu ugugauuggc guuuuuu 107

<210> 33
<211> 107
<212> RNA
<213> *Vibrio parahaemolyticus*

<400> 33
ugacccuuuc uaagccgagg gucaccuagc caacugacgu uguuagugaa cccaauuguu 60
cacaaguaua uacagccaau cacacaccuu gugguuggcu uuuuuuu 107

<210> 34
<211> 93
<212> RNA
<213> *Vibrio vulnificus*

<400> 34
ugacccucg ggucaccuag ccaacugacg uuguuaguga accuaguguu cacaauugau 60
agccaauagu gaaugacug uuggcuuuuu uuu 93

<210> 35
<211> 110
<212> RNA
<213> *Vibrio vulnificus*

<400> 35
cgacccuuau uaagccgagg gucaccuagc caacugacgu uguuagugaa uacacauugu 60

ucacaucaua cauaagccaa ucgcacuuau uuugcgguug guuuuuuuuu 110

<210> 36
 <211> 108
 <212> RNA
 <213> *Vibrio vulnificus*

<400> 36
 ugacccuuau uaagccgagg gucaccuagc caacugacgu uguuagugaa cuugauuugu 60
 ucacauguau auaagccaa ucgcacuuau gcggguuggc cuuuuuuu 108

<210> 37
 <211> 107
 <212> RNA
 <213> *Vibrio vulnificus*

<400> 37
 ugacccuuau uaagccgagg gucaccuagc caacugacgu uguuagugaa uaaugacuug 60
 uucacacaua uauacggcca aacaccugau uguguuuggc cuuuuuuu 107

<210> 38
 <211> 108
 <212> RNA
 <213> *Vibrio vulnificus*

<400> 38
 ugacccuuuu uaagccgagg gucaccuagc caacugacgu uguuagugaa ccugauuguu 60
 cacaauuaua uacagccaa caccucuau ugugauggc uuuuuuuu 108

<210> 39
 <211> 264
 <212> DNA
 <213> *Vibrio harveyi*

<400> 39
 atggctaagg ggcaatctct acaagaccca ttcctaaatg cgctacgtcg tgagcgtatc 60
 ccggtatcta tctaccttgt gaacggtatc aaactgcaag gtcagatcga atctttcgat 120
 cagttcgtga tcctattgaa gaacactgtt aaccaaattg tgtacaagca cgcaatctct 180
 accgttggtc cggctcgtcc agtgagccac cacagtgggt atcgtcctca aggtgaccgt 240
 ccacaagaga aatctgaaga ttaa 264

<210> 40
 <211> 87
 <212> PRT
 <213> *Vibrio harveyi*

<400> 40
 Met Ala Lys Gly Gln Ser Leu Gln Asp Pro Phe Leu Asn Ala Leu Arg
 1 5 10 15
 Arg Glu Arg Ile Pro Val Ser Ile Tyr Leu Val Asn Gly Ile Lys Leu
 20 25 30
 Gln Gly Gln Ile Glu Ser Phe Asp Gln Phe Val Ile Leu Leu Lys Asn
 35 40 45

Thr Val Asn Gln Met Val Tyr Lys His Ala Ile Ser Thr Val Val Pro
 50 55 60

Ala Arg Pro Val Ser His His Ser Gly Asp Arg Pro Gln Gly Asp Arg
 65 70 75 80

Pro Gln Glu Lys Ser Glu Asp
 85

<210> 41
 <211> 264
 <212> DNA
 <213> *Vibrio cholerae*

<400> 41
 atggctaagg ggcaatctct acaagaccca tttctgaatg cactacgtcg tgaacgtatc 60
 cctgtttcta tctaccttgt gaacggcatt aaactgcaag gtcagatcga atcatttgat 120
 caatttggtga tcttgctgaa gaacacagta aaccaaattgg tttacaagca tgcgatttct 180
 actgtgggttc ctgctcgtcc agttagccac cacagcggcg accgcccagc atcggatcgt 240
 ccagcagaga agtctgaaga gtaa 264

<210> 42
 <211> 87
 <212> PRT
 <213> *Vibrio cholerae*

<400> 42
 Met Ala Lys Gly Gln Ser Leu Gln Asp Pro Phe Leu Asn Ala Leu Arg
 1 5 10 15

Arg Glu Arg Ile Pro Val Ser Ile Tyr Leu Val Asn Gly Ile Lys Leu
 20 25 30

Gln Gly Gln Ile Glu Ser Phe Asp Gln Phe Val Ile Leu Leu Lys Asn
 35 40 45

Thr Val Asn Gln Met Val Tyr Lys His Ala Ile Ser Thr Val Val Pro
 50 55 60

Ala Arg Pro Val Ser His His Ser Gly Asp Arg Pro Ala Ser Asp Arg
 65 70 75 80

Pro Ala Glu Lys Ser Glu Glu
 85

<210> 43
 <211> 16
 <212> DNA
 <213> *Vibrio cholerae*

<220>
 <221> modified base
 <222> (7)..(11)
 <223> a, c, g, or t

<400> 43
 tggcacnnnn nttgcw

<210> 44
<211> 82
<212> RNA
<213> *Vibrio cholerae*

<400> 44
ccgaaauuca ucguuuauug uuuuauuagu aaucucguuu uacgaguuag uuguugaguu 60
aaccguuccu auauggggau ac 82

<210> 45
<211> 81
<212> RNA
<213> *Vibrio harveyi*

<400> 45
acgaaauucg uugauaaauu uauuaguuaa uccccugaua gggguuuuau aguugaguu 60
accguuccu uuaccuaaua c 81

<210> 46
<211> 13
<212> DNA
<213> Unknown Organism

<220>
<223> Description of Unknown Organism: Consensus
sequence from various organisms

<400> 46
ttgcawwtg caa 13